slide 1 presented by susan chang at 2014 asco annual meeting
TRANSCRIPT
Slide 1
Presented By Susan Chang at 2014 ASCO Annual Meeting
Imaging assessment in Neuro-Oncology
Presented By Susan Chang at 2014 ASCO Annual Meeting
Limitation: Early Pseudo-Progression <br />after radiochemotherapy<br />
Presented By Susan Chang at 2014 ASCO Annual Meeting
Slide 4
Presented By Susan Chang at 2014 ASCO Annual Meeting
Limitation- Determination of enhancing and non- enhancing tumor burden post antiangiogenic treatment
Presented By Susan Chang at 2014 ASCO Annual Meeting
Slide 6
Presented By Susan Chang at 2014 ASCO Annual Meeting
# 2007 Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab- Huang et al
Presented By Susan Chang at 2014 ASCO Annual Meeting
Assessment of RANO
Presented By Susan Chang at 2014 ASCO Annual Meeting
RANO-Endpoints and Trial Design
Presented By Susan Chang at 2014 ASCO Annual Meeting
# 2005- Final Results of APG101_CD_002: <br />APG101 + Reirradiation versus Reirradiation in the Treatment of Patients with Progressive Glioblastoma: Platten et al
Presented By Susan Chang at 2014 ASCO Annual Meeting
Results
Presented By Susan Chang at 2014 ASCO Annual Meeting
APG101_CD_002: Novel Biomarker for OS
Presented By Susan Chang at 2014 ASCO Annual Meeting
Slide 13
Presented By Susan Chang at 2014 ASCO Annual Meeting
Slide 14
Presented By Susan Chang at 2014 ASCO Annual Meeting
Slide 15
Presented By Susan Chang at 2014 ASCO Annual Meeting
Results for ICT-107 Ph II
Presented By Susan Chang at 2014 ASCO Annual Meeting
Authors conclusions/Comments
Presented By Susan Chang at 2014 ASCO Annual Meeting
Authors conclusions/Comments
Presented By Susan Chang at 2014 ASCO Annual Meeting
What “success” in a phase II trial warrants phase III evaluation?
Presented By Susan Chang at 2014 ASCO Annual Meeting
Future RANO efforts
Presented By Susan Chang at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Susan Chang at 2014 ASCO Annual Meeting